NCT01827943View on ClinicalTrials.gov

Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2016

Conditions
Relapsed Bladder Cancer
Interventions
DRUG

Temsirolimus

Temsirolimus

Trial Locations (9)

14076

Centre François Baclesse, Caen

31052

Institut Claudius Regaud, Toulouse

31059

CHU de Toulouse, Toulouse

33076

CHU de Bordeaux, Bordeaux

63011

Centre Jean Perrin, Clermont-Ferrand

69373

Centre Léon Bérard, Lyon

75230

Hôpital d'instruction des armées du Val-de-Grâce, Paris

76031

CHU de Rouen, Rouen

94010

CHU Henri Mondor, Créteil

Sponsors

Lead Sponsor

Institut Bergonié
All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Institut Bergonié

OTHER